




EMLc
ATC codes: [J01BA01](#)

Indication	Bacterial meningitis <span>ICD11 code: <a href="#">8E71.0Z</a></span>
INN	Chloramphenicol
Medicine type	Chemical agent
Antibiotic groups	<span>A</span> ACCESS
List type	Core (EML) (EMLc)
Additional notes	Oily suspension for injection formulation is only for the presumptive treatment of epidemic meningitis in children older than 2 years and in adults.
Formulations	Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate) Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
EML status history	First added in 2017 ( <a href="#">TRS 1006</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Chloramphenicol</a> 
DrugBank	<a href="#">Chloramphenicol</a> 

## Expert Committee recommendation

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the deletion of oral formulations of chloramphenicol (capsule 250 mg and oral liquid 150 mg/5 mL (as palmitate)) from the EML and EMLc.

## EML recommendations: Bacterial meningitis

**First choice**

**Second choice**

cefotaxime

ampicillin

ceftriaxone

benzylpenicillin

amoxicillin

chloramphenicol

